Cargando…
Retraction Note to: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib‑mediated death via inhibiting the AMPK–Mfn2 signaling pathway
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936120/ https://www.ncbi.nlm.nih.gov/pubmed/31892858 http://dx.doi.org/10.1186/s12935-019-1084-7 |
| _version_ | 1783483686739509248 |
|---|---|
| author | Song, Jie Zhao, Wei Lu, Chang Shao, Xue |
| author_facet | Song, Jie Zhao, Wei Lu, Chang Shao, Xue |
| author_sort | Song, Jie |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6936120 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2019 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-69361202019-12-31 Retraction Note to: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib‑mediated death via inhibiting the AMPK–Mfn2 signaling pathway Song, Jie Zhao, Wei Lu, Chang Shao, Xue Cancer Cell Int Retraction Note BioMed Central 2019-12-30 /pmc/articles/PMC6936120/ /pubmed/31892858 http://dx.doi.org/10.1186/s12935-019-1084-7 Text en © The Author(s) 2019 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Retraction Note Song, Jie Zhao, Wei Lu, Chang Shao, Xue Retraction Note to: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib‑mediated death via inhibiting the AMPK–Mfn2 signaling pathway |
| title | Retraction Note to: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib‑mediated death via inhibiting the AMPK–Mfn2 signaling pathway |
| title_full | Retraction Note to: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib‑mediated death via inhibiting the AMPK–Mfn2 signaling pathway |
| title_fullStr | Retraction Note to: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib‑mediated death via inhibiting the AMPK–Mfn2 signaling pathway |
| title_full_unstemmed | Retraction Note to: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib‑mediated death via inhibiting the AMPK–Mfn2 signaling pathway |
| title_short | Retraction Note to: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib‑mediated death via inhibiting the AMPK–Mfn2 signaling pathway |
| title_sort | retraction note to: lats2 overexpression attenuates the therapeutic resistance of liver cancer hepg2 cells to sorafenib‑mediated death via inhibiting the ampk–mfn2 signaling pathway |
| topic | Retraction Note |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6936120/ https://www.ncbi.nlm.nih.gov/pubmed/31892858 http://dx.doi.org/10.1186/s12935-019-1084-7 |
| work_keys_str_mv | AT songjie retractionnotetolats2overexpressionattenuatesthetherapeuticresistanceoflivercancerhepg2cellstosorafenibmediateddeathviainhibitingtheampkmfn2signalingpathway AT zhaowei retractionnotetolats2overexpressionattenuatesthetherapeuticresistanceoflivercancerhepg2cellstosorafenibmediateddeathviainhibitingtheampkmfn2signalingpathway AT luchang retractionnotetolats2overexpressionattenuatesthetherapeuticresistanceoflivercancerhepg2cellstosorafenibmediateddeathviainhibitingtheampkmfn2signalingpathway AT shaoxue retractionnotetolats2overexpressionattenuatesthetherapeuticresistanceoflivercancerhepg2cellstosorafenibmediateddeathviainhibitingtheampkmfn2signalingpathway |